IMA 942 - Immatics biotechnologies
Latest Information Update: 12 Sep 2024
At a glance
- Originator Immatics N.V.
- Class Antineoplastics; Cancer vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastric cancer
Most Recent Events
- 21 Aug 2024 Preclinical trials in Gastric cancer in Germany (Parenteral), prior to August 2024
- 21 Aug 2024 Immantics plans a phase I trial for Gastric cancer